Kirill's research is aimed at finding new ways to sensitize tumor cells when they are exposed to DNA-damaging agents such as doxorubicin, etoposide, and irinotecan. At the moment, the project is studying the action of a small molecular potential inhibitor of the p21 protein, which - in turn - is one of the main regulators of the cell cycle.